The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 12, 2012, Pages 1533-1543

  Cimmino, Giovanni ^a   Conte, Stefano ^a   Morello, Alberto ^a   D'elia, Saverio ^a   Marchese, Valeria ^a   Golino, Paolo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

acute coronary syndromes; coagulation; tissue factor; vulnerable blood

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PROCOAGULANT; PROTEINASE ACTIVATED RECEPTOR 2; SUPEROXIDE; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ATHERECTOMY; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COMPARATIVE STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; HUMAN; IN VIVO STUDY; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOGENICITY; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; BLOOD COAGULATION; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTES; PLAQUE, ATHEROSCLEROTIC;

EID: 84871522234     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.157     Document Type: Review

References (105)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104(22), 2746-2753 (2001). (Pubitemid 33108145)
2. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur. Heart J. 25(14), 1197-1207 (2004). (Pubitemid 38891569)
3. Fefer P, Knudtson ML, Cheema AN et al. Current perspectives on coronary chronic total occlusions: The Canadian Multicenter Chronic Total Occlusions Registry. J. Am. Coll. Cardiol. 59(11), 991-997 (2012).
4. Badimon JJ, Ibanez B, Cimmino G. Genesis and dynamics of atherosclerotic lesions: Implications for early detection. Cerebrovasc. Dis. 27(Suppl. 1), 38-47 (2009).
5. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: Pathogenesis and therapeutic approach. Cardiovasc. Pathol. 13(3), 125-138 (2004). (Pubitemid 38470089)
6. Lowe GD. Local inflammation, endothelial dysfunction and fibrinolysis in coronary heart disease. Clin. Sci. 110(3), 327-328 (2006). (Pubitemid 43341634)
7. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. Circ. Res. 88(10), 998-1003 (2001). (Pubitemid 34137111)
8. Toschi V, Gallo R, Lettino M et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95(3), 594-599 (1997). (Pubitemid 27063034)
9. Hutter R, Valdiviezo C, Sauter BV et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: Evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 109(16), 2001-2008 (2004). (Pubitemid 38544491)
10. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann. Intern. Med. 134(3), 224-238 (2001). (Pubitemid 32113325)
11. Sambola A, Osende J, Hathcock J et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107(7), 973-977 (2003). (Pubitemid 36258719)
12. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338(23), 1650-1656 (1998). (Pubitemid 28267909)
13. Nemetz PN, Roger VL, Ransom JE, Bailey KR, Edwards WD, Leibson CL. Recent trends in the prevalence of coronary disease: A population-based autopsy study of nonnatural deaths. Arch. Intern. Med. 168(3), 264-270 (2008). (Pubitemid 351281671)
14. Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics Y 2011 update: A report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
15. Smith SC Jr. Risk-reduction therapy: The challenge to change. Presented at the 68th scientific sessions of the American Heart Association November 13, 1995 Anaheim, California. Circulation 93(12), 2205-2211 (1996). (Pubitemid 126425271)
16. Hansson GK, Klareskog L. Pulling down the plug on atherosclerosis: Cooling down the inflammasome. Nat. Med. 17(7), 790-791 (2011).
17. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317-325 (2011).
18. Li JJ, Jiang H, Huang CX et al. Elevated level of plasma C-reactive protein in patients with unstable angina: Its relations with coronary stenosis and lipid profile. Angiology 53(3), 265-272 (2002). (Pubitemid 34525863)
19. Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002). (Pubitemid 36019640)
20. Shah PK. Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 41(4 Suppl. S), 15SY22S (2003). (Pubitemid 36223342)
21. Li JJ, Fang CH, Chen MZ, Chen X, Lee SW. Activation of nuclear factor-κB and correlation with elevated plasma c-reactive protein in patients with unstable angina. Heart. Lung Circ. 13(2), 173-178 (2004). (Pubitemid 38877989)
22. Li JJ, Wang HR, Huang CX, Xue JL, Li GS. Enhanced inflammatory response of blood monocytes to C-reactive protein in patients with unstable angina. Clin. Chim. Acta 352(1-2), 127-133 (2005).
23. Shah PK. Inflammation and plaque vulnerability. Cardiovasc. Drugs Ther. 23(1), 31-40 (2009).
24. Michowitz Y, Arbel Y, Wexler D et al. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int. J. Cardiol. 125(3), 347-351 (2008). (Pubitemid 351419249)
25. Suleiman M, Khatib R, Agmon Y et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J. Am. Coll. Cardiol. 47(5), 962-968 (2006).
26. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of c-reactive protein in risk assessment. Am. J. Med. 116 (Suppl. 6A), 9SY16S (2004).
27. Koenig W, Sund M, Fröhlich M et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99(2), 237-242 (1999). (Pubitemid 29056365)
28. Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: Linking obesity to vascular inflammation. J. Am. Coll. Cardiol. 46(6), 1112-1113 (2005). (Pubitemid 41316523)
29. Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108(16), 1930-1932 (2003). (Pubitemid 37296536)
30. De Rosa S, Cirillo P, Pacileo M, Di Palma V, Paglia A, Chiariello M. Leptin stimulated C-reactive protein production by human coronary artery endothelial cells. J. Vasc. Res. 46(6), 609-617 (2009).
31. Forte L, Cimmino G, Loffredo F et al. C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. Int. J. Cardiol. 152(1), 7-12 (2011).
32. Cirillo P, Golino P, Calabrò P et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc. Res. 68(1), 47-55 (2005). (Pubitemid 41253555)
33. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc. Res. 58(1), 186-195 (2003). (Pubitemid 36351637)
34. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 107(3), 398-404 (2003).
35. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102(18), 2165-2168 (2000).
36. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103(21), 2531-2534 (2001). (Pubitemid 32521959)
37. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106(8), 913-919 (2002). (Pubitemid 34925323)
38. Guo S, Meng S, Chen B, Liu J, Gao L, Wu Y. C-reactive protein can influence the proliferation, apoptosis, and monocyte chemotactic protein-1 production of human umbilical vein endothelial cells. DNA Cell Biol. 30(3), 157-162 (2011).
39. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98(11), 2572-2579 (1996). (Pubitemid 26415078)
40. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82(2), 513-520 (1993). (Pubitemid 23206115)
41. Xie L, Chang L, Guan Y, Wang X. C-reactive protein augments interleukin-8 secretion in human peripheral blood monocytes. J. Cardiovasc. Pharmacol. 46(5), 690-696 (2005). (Pubitemid 41527763)
42. Galvede Rochemonteix B, Wiktorowicz K, Kushner I, Dayer JM. C-reactive protein increases production of IL-1 α, IL-1 β, and TNF-α, and expression of mrna by human alveolar macrophages. J. Leukoc. Biol. 53, 439-445 (1993). (Pubitemid 23159886)
43. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90(2), 775-778 (1994). (Pubitemid 24242744)
44. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90(4), 1669-1678 (1994). (Pubitemid 24320913)
45. den Dekker WK, Tempel D, Bot I et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler. Thromb. Vasc. Biol. 32(8), 1960-1969 (2012).
46. Doherty TM. T-cell regulation of macrophage function. Curr. Opin. Immunol. 7(3), 400-404 (1995).
47. Liuzzo G, Kopecky SL, Frye RL et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 100(21), 2135-2139 (1999).
48. Nakajima T, Goek O, Zhang X et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ. Res. 93(2), 106-113 (2003). (Pubitemid 36919697)
49. Caligiuri G, Paulsson G, Nicoletti A, Maseri A, Hansson GK. Evidence for antigen-driven T-cell response in unstable angina. Circulation 102(10), 1114-1119 (2000).
50. De Palma R, Del Galdo F, Abbate G et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: Evidence for a local, intracoronary immunologic mechanism. Circulation 113(5), 640-646 (2006).
51. Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: Break of tolerance in the artery wall. Thromb. Haemost. 106(5), 779-786 (2011).
52. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immunol. 183(3), 1715-1723 (2009).
53. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J. Innate Immun. 2(4), 325-333 (2010).
54. Cirillo P, Golino P, Piscione F et al. Transcoronary Th-17 lymphocytes and acute coronary syndromes: New evidence from the crime scene? Int. J. Cardiol. 153(2), 215-216 (2011).
55. Dahlbäck B. Blood coagulation. Lancet 355(9215), 1627-1632 (2000). (Pubitemid 30240513)
56. Ruggeri ZM. Structure and function of von Willebrand factor. Thromb. Haemost. 82(2), 576-584 (1999).
57. Jackson SP. The growing complexity of platelet aggregation. Blood 109(12), 5087-5095 (2007). (Pubitemid 46890522)
58. Coughlin SR. How the protease thrombin talks to cells. Proc. Natl Acad. Sci. USA 96(20), 11023-11027 (1999). (Pubitemid 29487321)
59. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 364(18), 1746-1760 (2011).
60. Renné T, Pozgajová M, Grüner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202(2), 271-281 (2005). (Pubitemid 41043823)
61. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb. Haemost. 87(4), 774-776 (2002). (Pubitemid 34302972)
62. Müller F, Mutch NJ, Schenk WA et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139(6), 1143-1156 (2009).
63. Zito F, Lowe GD, Rumley A, McMahon AD, Humphries SE; WOSCOPS Study Group West of Scotland Coronary Prevention Study. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 165(1), 153-158 (2002). (Pubitemid 35223177)
64. Govers-Riemslag JW, Smid M, Cooper JA et al. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J. Thromb. Haemost. 5(9), 1896-1903 (2007). (Pubitemid 47288948)
65. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: Results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 122(18), 1854-1861 (2010).
66. Frenette PS, Denis CV, Weiss L et al. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J. Exp. Med. 191(8), 1413-1422 (2000). (Pubitemid 30227127)
67. Hrachovinová I, Cambien B, Hafezi-Moghadam A et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. 9(8), 1020-1025 (2003). (Pubitemid 37021781)
68. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol. Med. 10(4), 171-178 (2004). (Pubitemid 38410975)
69. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20(5), 1262-1275 (2000). (Pubitemid 30262927)
70. Cheruvu PK, Finn AV, Gardner C et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: A pathologic study. J. Am. Coll. Cardiol. 50(10), 940-949 (2007). (Pubitemid 47313605)
71. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: Role of healed plaque disruption. Heart 82(3), 265-268 (1999). (Pubitemid 29429594)
72. Stone GW, Maehara A, Lansky AJ et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364(3), 226-235 (2011).
73. Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: Another view of thrombosis. Proc. Natl Acad. Sci. USA 96(5), 2311-2315 (1999). (Pubitemid 29117911)
74. Bach RR. Tissue factor encryption. Arterioscler. Thromb. Vasc. Biol. 26(3), 456-461 (2006).
75. Rao LV, Kothari H, Pendurthi UR. Tissue factor encryption and decryption: Facts and controversies. Thromb. Res. 129(Suppl. 2), S13-S17 (2012).
76. Lechner D, Weltermann A. Circulating tissue factor-exposing microparticles. Thromb. Res. 122(Suppl. 1), S47-S54 (2008).
77. Chargaff E, West R. The biological significance of the thromboplastic protein of blood. J. Biol. Chem. 166(1), 189-197 (1946).
78. Davizon P, López JA. Microparticles and thrombotic disease. Curr. Opin. Hematol. 16(5), 334-341 (2009).
79. Leroyer AS, Isobe H, Lesèche G et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J. Am. Coll. Cardiol. 49(7), 772-777 (2007). (Pubitemid 46240708)
80. Rautou PE, Leroyer AS, Ramkhelawon B et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ. Res. 108(3), 335-343 (2011).
81. Rauch U, Bonderman D, Bohrmann B et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96(1), 170-175 (2000). (Pubitemid 30456467)
82. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat. Med. 9(4), 458-462 (2003). (Pubitemid 36460081)
83. van den Berg YW, Versteeg HH. Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes? Hamostaseologie. 30(3), 144-149 (2010).
84. Srinivasan R, Bogdanov VY. Splice variants of Tissue Factor and integrin-mediated signaling. Thromb. Res. 129(Suppl. 2), S34-S37 (2012).
85. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 96(12), 1233-1239 (2005). (Pubitemid 40962100)
86. Censarek P, Bobbe A, Grandoch M, Schrör K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb. Haemost. 97(1), 11-14 (2007). (Pubitemid 46242381)
87. Hobbs JE, Zakarija A, Cundiff DL et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb. Res. 120(Suppl. 2), S13-S21 (2007). (Pubitemid 350101769)
88. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler. Thromb. Vasc. Biol. 29(12), 1989-1996 (2009).
89. Khorana AA, Francis CW, Menzies KE et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haemost. 6(11), 1983-1985 (2008).
90. Wang JG, Manly D, Kirchhofer D, Pawlinski R, Mackman N. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J. Thromb. Haemost. 7(7), 1092-1098 (2009).
91. Owens AP 3rd, Passam FH, Antoniak S et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J. Clin. Invest. 122(2), 558-568 (2012).
92. Bogdanov VY, Cimmino G, Tardos JG, Tunstead JR, Badimon JJ. Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: Limitations of a commercial assay. J. Thromb. Haemost. 7(5), 894-897 (2009).
93. Cimmino G, Cirillo P, Petrillo G et al. Decreased blood-borne tissue factor activity in patients presenting with acute coronary syndrome: Should the old paradigm be revisited? Circulation 122, Abstract A19396 (2010).
94. Antoniak S, Rojas M, Spring D et al. Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 30(11), 2136-2142 (2010).
95. Carmeliet P, Mackman N, Moons L et al. Role of tissue factor in embryonic blood vessel development. Nature 383(6595), 73-75 (1996). (Pubitemid 26296462)
96. Randolph GJ, Luther T, Albrecht S, Magdolen V, Muller WA. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 92(11), 4167-4177 (1998). (Pubitemid 28544332)
97. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb. Haemost. 75(3), 389-392 (1996). (Pubitemid 26099699)
98. Poulsen LK, Jacobsen N, Sørensen BB et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J. Biol. Chem. 273(11), 6228-6232 (1998). (Pubitemid 28144709)
99. Pendurthi UR, Alok D, Rao LV. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Up-regulation of poly(A) polymerase. Proc. Natl Acad. Sci. USA 94(23), 12598-12603 (1997). (Pubitemid 27492574)
100. Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res. 58(19), 4461-4467 (1998). (Pubitemid 28450052)
101. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J. Biol. Chem. 275(9), 6580-6585 (2000). (Pubitemid 30129959)
102. Cirillo P, Calì G, Golino P et al. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109(23), 2911-2916 (2004). (Pubitemid 38780307)
103. Golino P, Ragni M, Cirillo P et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat. Med. 2(1), 35-40 (1996). (Pubitemid 26028070)
104. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur. J. Clin. Invest. 33(11), 941-948 (2003). (Pubitemid 37421591)
105. Moertl D, Berger R, Hammer A et al. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb. Haemost. 106(3), 457-465 (2011).